Primary study · included by 1 review

A Functional Scoring System Based on Salivary Gland Scintigraphy for Evaluating Salivary Gland Dysfunction Secondary to 131I therapy in Patients with Differentiated Thyroid Carcinoma.

Maruoka 2017 · Maruoka Yasuhiro, Baba Shingo, Isoda Takuro, et al. · Journal of clinical and diagnostic research : JCDR · 2017

Included by

Salivary and lacrimal disorders in patients treated with radioiodine for differentiated thyroid cancer.
Non-Cochrane · prognostic · 2026 · cited as Maruoka 2017 · Reference list; Fig. 1-3
Outcome this study informsPooled effectEvidenceCertainty
Xerostomia (pooled prevalence)
Radioiodine (I131) therapy · within 2 months after RIT
Prevalence 0.60 [0.28, 0.85]3 studies · 1502 participantsGRADE not reported
Xerostomia
High administered I131 activity (study-specific thresholds) vs Low administered I131 activity (study-specific thresholds)
OR 7.14 [2.02, 25.26]3 studiesGRADE not reported
Xerostomia (pooled prevalence)
Radioiodine (I131) therapy · between 6 months and 1 year after RIT
Prevalence 0.19 [0.14, 0.25]5 studies · 885 participantsGRADE not reported
Xerostomia
High administered I131 activity (study-specific thresholds) vs Low administered I131 activity (study-specific thresholds)
OR 4.23 [1.04, 17.15]4 studiesGRADE not reported

1 including review in total.